Nothing Special   »   [go: up one dir, main page]

WO2001023563A3 - Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors - Google Patents

Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors Download PDF

Info

Publication number
WO2001023563A3
WO2001023563A3 PCT/US2000/026528 US0026528W WO0123563A3 WO 2001023563 A3 WO2001023563 A3 WO 2001023563A3 US 0026528 W US0026528 W US 0026528W WO 0123563 A3 WO0123563 A3 WO 0123563A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormones
compositions
therapeutic methods
hormone receptors
morphogenic proteins
Prior art date
Application number
PCT/US2000/026528
Other languages
French (fr)
Other versions
WO2001023563A2 (en
Inventor
John C Lee
Lee-Chuan C Yeh
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Priority to CA002385887A priority Critical patent/CA2385887A1/en
Priority to AU76191/00A priority patent/AU773990B2/en
Priority to EP00965478A priority patent/EP1220909A2/en
Priority to JP2001526945A priority patent/JP2003510338A/en
Publication of WO2001023563A2 publication Critical patent/WO2001023563A2/en
Publication of WO2001023563A3 publication Critical patent/WO2001023563A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention features devices and methods for inducing tissue formation in a mammal, involving the use of a morphogenic protein, a hormone and a soluble receptor of the hormone. The hormone and receptor thereof are used to enhance the tissue inductive activity of the morphogenic protein.
PCT/US2000/026528 1999-09-27 2000-09-27 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors WO2001023563A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002385887A CA2385887A1 (en) 1999-09-27 2000-09-27 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
AU76191/00A AU773990B2 (en) 1999-09-27 2000-09-27 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
EP00965478A EP1220909A2 (en) 1999-09-27 2000-09-27 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
JP2001526945A JP2003510338A (en) 1999-09-27 2000-09-27 Compositions and methods of treatment using morphogenic proteins, hormones and hormone receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15626199P 1999-09-27 1999-09-27
US60/156,261 1999-09-27

Publications (2)

Publication Number Publication Date
WO2001023563A2 WO2001023563A2 (en) 2001-04-05
WO2001023563A3 true WO2001023563A3 (en) 2001-10-04

Family

ID=22558805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026528 WO2001023563A2 (en) 1999-09-27 2000-09-27 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors

Country Status (5)

Country Link
EP (1) EP1220909A2 (en)
JP (1) JP2003510338A (en)
AU (1) AU773990B2 (en)
CA (1) CA2385887A1 (en)
WO (1) WO2001023563A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029630D1 (en) * 2003-03-04 2010-12-02 Technology Dev Co Ltd Injectable long-acting insulin preparation and process for its preparation and use
WO2005111069A2 (en) * 2004-05-11 2005-11-24 Stryker Corporation Morphogenic proteins and stimulatory factors in gene therapy
US20140212380A1 (en) * 2011-06-10 2014-07-31 Universite Libre De Bruxelles Targets and agents for the treatment of impaired bone fracture healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021447A1 (en) * 1995-12-12 1997-06-19 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
WO1999021574A2 (en) * 1997-10-27 1999-05-06 Creative Biomolecules, Inc. Enhancement of morphogen activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021447A1 (en) * 1995-12-12 1997-06-19 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
WO1999021574A2 (en) * 1997-10-27 1999-05-06 Creative Biomolecules, Inc. Enhancement of morphogen activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EBENDAL T. ET AL.: "Bone morphogenetic proteins and their receptors: potential functions in the brain", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 51, no. 2, 5 January 1998 (1998-01-05), pages 139 - 146, XP000952988, ISSN: 0360-4012 *
GUO X. ET AL.: "Leukemia Inhibitory Factor and Ciliary Neurotrophic Factor cause dendritic retraction in cultured rat sympathetic neurons", THE JOURNAL OF NEUROSCIENCE, vol. 19, no. 6, 15 March 1999 (1999-03-15), pages 2113 - 2121, XP000990891 *
REDDI A.H. AND CUNNINGHAM N.S.: "Initiation and promotion of bone differentiation by Bone Morphogenetic Proteins", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 8, no. Suppl. 2, December 1993 (1993-12-01), pages S499 - S502, XP000990887 *
ROSE-JOHN S. AND HEINRICH P.C.: "Soluble receptors for cytokines and growth factors: generation and biological function", BIOCHEMICAL JOURNAL, vol. 300, 1994, pages 281 - 290, XP000198415, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
WO2001023563A2 (en) 2001-04-05
AU7619100A (en) 2001-04-30
JP2003510338A (en) 2003-03-18
EP1220909A2 (en) 2002-07-10
CA2385887A1 (en) 2001-04-05
AU773990B2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
HUP0303976A3 (en) Combination therapy using anti-egfr antibodies and hormone antagonists
WO1999060119A3 (en) Multivalent t cell receptor complexes
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
NL1032282A1 (en) N-terminal mono-pegylated human growth hormone conjugates and process for their preparation.
BG66075B1 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
IL152384A0 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO1999017755A3 (en) Medicaments
WO2004059285A3 (en) Tumor killing/tumor regression using cxcr4 antagonists
HUP0200429A2 (en) Soluble receptor br43x2 and methods of using
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
DK1820494T3 (en) Microparticles consisting of estradiol and cholesterol
AU4134101A (en) Hormone receptor functional entities and methods of their use
AU4834900A (en) Antagonists of gonadotropin releasing hormone
IL144031A0 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU6232300A (en) Receptors and associated proteins
AU6228000A (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
IL206566A0 (en) Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
WO2001023563A3 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
AU2001269013A1 (en) Human galanin receptor-like g protein coupled receptor
AU4742101A (en) Antagonists of gonadotropin releasing hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2385887

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 76191/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526945

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000965478

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965478

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 76191/00

Country of ref document: AU